Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMTNASDAQ:ITCINASDAQ:RARXNASDAQ:VIE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AITCIIntra-Cellular Therapies$131.87$131.42$64.09▼$131.98$14.05B0.691.47 million shsN/ARARXRa Pharmaceuticals$47.99$47.99$19.64▼$48.02$2.27B1.051.16 million shs30,200 shsVIEViela Bio$53.01$53.01$25.02▼$65.00$2.91B0.431.07 million shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%ITCIIntra-Cellular Therapies0.00%0.00%0.00%+3.77%+81.31%RARXRa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VIEViela Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AITCIIntra-Cellular Therapies0.8818 of 5 stars1.10.00.04.51.11.70.6RARXRa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVIEViela BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune Therapeutics 0.00N/AN/AN/AITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideRARXRa Pharmaceuticals 0.00N/AN/AN/AVIEViela Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ITCI, VIE, RARX, and AIMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.002/24/2025ITCIIntra-Cellular TherapiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$140.00 ➝ $132.002/21/2025ITCIIntra-Cellular TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 5/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44RARXRa Pharmaceuticals$3M757.11N/AN/A$5.56 per share8.63VIEViela Bio$50M58.26N/AN/A$7.14 per share7.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)RARXRa Pharmaceuticals-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/AVIEViela Bio-$86.43M-$7.02N/AN/AN/AN/A-33.97%-31.49%N/ALatest ITCI, VIE, RARX, and AIMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/AVIEViela BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40ITCIIntra-Cellular TherapiesN/A7.667.51RARXRa Pharmaceuticals0.0114.7814.79VIEViela BioN/A19.5119.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%ITCIIntra-Cellular Therapies92.33%RARXRa PharmaceuticalsN/AVIEViela Bio46.98%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%ITCIIntra-Cellular Therapies2.60%RARXRa Pharmaceuticals4.30%VIEViela Bio31.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableRARXRa Pharmaceuticals7247.33 millionN/AOptionableVIEViela Bio16654.95 millionN/ANot OptionableITCI, VIE, RARX, and AIMT HeadlinesRecent News About These CompaniesBETDAQ app downloadDecember 30, 2024 | bwsmartcities.businessworld.indc vs punjab 2022December 30, 2024 | everythingexperiential.businessworld.inKhelo India Khelo lucky 3 result todayDecember 30, 2024 | bweducation.businessworld.in777 Win SooterDecember 30, 2024 | bwdisrupt.businessworld.inTherapeutic Drug Monitoring in Rheumatology Has Potential but Faces a Host of HurdlesOctober 23, 2024 | medscape.comAnti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia GravisOctober 16, 2024 | msn.comDmitry Bivol: Biography, record, fights and moreOctober 10, 2024 | espn.comRGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-DollarOctober 9, 2024 | de.investing.comRoche takes on Alexion as FDA approves satralizumab in NMOSDSeptember 29, 2024 | pharmaphorum.comREGENXBIO Inc.: REGENXBIO Appoints Mitchell Chan as Chief Financial OfficerSeptember 17, 2024 | finanznachrichten.deREGENXBIO ernennt Mitchell Chan zum neuen CFO in WachstumsphaseSeptember 17, 2024 | de.investing.comRegenxbio Names Mitchell Chan CFOSeptember 17, 2024 | markets.businessinsider.comAstraZeneca spins out biotech to focus on autoimmune candidatesAugust 27, 2024 | pharmaphorum.comComplement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsightAugust 21, 2024 | prnewswire.co.ukMinority Stockholder Was Not a Controller Because Plaintiff Did Not Adequately Plead Actual Control of the Company’s Business AffairsAugust 21, 2024 | law.comFactor D Complement Inhibitor Market Will Witness Robust Growth with Emerging Therapies by 2034 | DelveInsightAugust 19, 2024 | finance.yahoo.comLitigation Leaders: Adam Siegel of Freshfields on Four ‘Cs’ of the Firm’s Litigation PracticeAugust 19, 2024 | law.com2024 Fire Awards: Meet this year's Ablaze honoreesAugust 16, 2024 | bizjournals.comAmgen Touts Q2 Growth Bolstered by Horizon Buy, Promising Obesity PipelineAugust 8, 2024 | biospace.comNovel Drug Made of Gold Nanocrystals Appears Safe in Multiple SclerosisApril 22, 2024 | medpagetoday.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAI Takes Over Search: Is Google's Dominance At Risk?By Ryan Hasson | April 7, 2025View AI Takes Over Search: Is Google's Dominance At Risk?XPO Buying $50 Million of Its Own Stock: Here's Why By Gabriel Osorio-Mazilli | April 16, 2025View XPO Buying $50 Million of Its Own Stock: Here's Why If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyBy Thomas Hughes | April 25, 2025View If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyBadger Meter Gets an Upgrade—2 Stocks That Could FollowBy Gabriel Osorio-Mazilli | April 4, 2025View Badger Meter Gets an Upgrade—2 Stocks That Could FollowGoodyear Gains Traction: Shares Climb as Key Catalysts AlignBy Jeffrey Neal Johnson | April 7, 2025View Goodyear Gains Traction: Shares Climb as Key Catalysts AlignITCI, VIE, RARX, and AIMT Company DescriptionsAimmune Therapeutics NASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Ra Pharmaceuticals NASDAQ:RARXRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.Viela Bio NASDAQ:VIEViela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
